Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Prepaid Assets: 2012-2025

Historic Prepaid Assets for Enanta Pharmaceuticals (ENTA) over the last 13 years, with Sep 2025 value amounting to $8.6 million.

  • Enanta Pharmaceuticals' Prepaid Assets fell 30.80% to $8.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.6 million, marking a year-over-year decrease of 30.80%. This contributed to the annual value of $8.6 million for FY2025, which is 30.80% down from last year.
  • As of Q3 2025, Enanta Pharmaceuticals' Prepaid Assets stood at $8.6 million, which was down 16.11% from $10.2 million recorded in Q2 2025.
  • Enanta Pharmaceuticals' 5-year Prepaid Assets high stood at $32.1 million for Q1 2021, and its period low was $8.6 million during Q3 2025.
  • Moreover, its 3-year median value for Prepaid Assets was $12.4 million (2024), whereas its average is $12.3 million.
  • Over the last 5 years, Enanta Pharmaceuticals' Prepaid Assets had its largest YoY gain of 62.04% in 2021, and its largest YoY loss of 58.91% in 2021.
  • Quarterly analysis of 5 years shows Enanta Pharmaceuticals' Prepaid Assets stood at $11.5 million in 2021, then surged by 55.97% to $17.9 million in 2022, then fell by 26.20% to $13.2 million in 2023, then fell by 19.34% to $10.7 million in 2024, then crashed by 30.80% to $8.6 million in 2025.
  • Its last three reported values are $8.6 million in Q3 2025, $10.2 million for Q2 2025, and $8.9 million during Q1 2025.